General
Preferred name
LULICONAZOLE
Synonyms
NND 502 ()
PR-2699 ()
Lulicon ()
NND-502 ()
Luzu ()
P&D ID
PD010680
CAS
187164-19-8
Tags
available
drug
Approved by
FDA
First approval
2013
Drug Status
approved
Drug indication
Dry eye disease
Tinea pedis
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Luliconazole is an imidazole antifungal drug. (GtoPdb)
INDICATION Luliconazole is indicated in adults aged 18 years and older for the topical treatment of fungal infections caused by Trichophyton rubrum and Epidermophyton floccosum, specifically tinea pedis, cruris, and corporis.;
Compound Sets
17
AdooQ Bioactive Compound Library
A11481
Cayman Chemical Bioactives
23120
ChEMBL Approved Drugs
CHEMBL2105689
ChEMBL Drugs
CHEMBL2105689
Drug Repurposing Hub
DrugBank
DB08933
DrugBank Approved Drugs
DB08933
DrugCentral
4813
DrugCentral Approved Drugs
4813
DrugMAP
DMT73J8
DrugMAP Approved Drugs
DMT73J8
Guide to Pharmacology
7366
MedChem Express Bioactive Compound Library
HY-14283
NCATS Inxight Approved Drugs
RE91AN4S8G
ReFrame library
Selleckchem Bioactive Compound Library
luliconazole
TargetMol Bioactive Compound Library
T2411
External IDs
28
Properties
(calculated by RDKit )
Molecular Weight
352.96
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
0
Rotatable Bonds
2
Ring Count
3
Aromatic Ring Count
2
cLogP
5.06
TPSA
41.61
Fraction CSP3
0.14
Chiral centers
1.0
Largest ring
6.0
QED
0.71
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Microbiology&virology
Anti-infection
Target
Antifungal
antibiotic
Fungal
Indication
tinea pedis, tinea cruris, tinea corporis
MOA
sterol demethylase inhibitor
Source data